Launch week offerEnds in00h00m00s

annual Promonthly Pro

Pedro Gaspar

Instituto Gulbenkian de Ciência

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Immunoregulation in Primary Antiphospholipid Syndrome

Open Date: 2022-04-01

Close Date: 2025-04-01

Articles (19)

Collaborators (4)

David A Isenberg

University College London

UNITED KINGDOM

Luis Graca

Gulbenkian Institute for Molecular Medicine

Danieli Andrade

University of Sao Paulo

Hannah Cohen

University College London Hospitals NHS Foundation Trust

UNITED KINGDOM

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Pedro Gaspar

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (19)

Collaborators (4)

David A Isenberg

Luis Graca

Danieli Andrade

Hannah Cohen

Make your next move.

Pedro Gaspar

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (19)

Dysregulation of helper, regulatory, and follicular CD4+ T cells in primary antiphospholipid syndrome: Immunopathology and implications for targeted immunomodulatory therapy

Comment on: Loss of antiphospholipid antibody positivity decreases the risk of recurrent thrombosis in thrombotic antiphospholipid syndrome: reply

Loss of antiphospholipid antibody positivity decreases the risk of recurrent thrombosis in thrombotic antiphospholipid syndrome

Delayed diagnosis contributes to increased thrombotic burden and independently predicts severe organ damage in thrombotic antiphospholipid syndrome

Risk factors for bleeding in patients with thrombotic antiphospholipid syndrome during antithrombotic therapy

Heterogeneity of T follicular regulatory cells: exploring their expanding ontogeny and differentiation pathways

ABS0043 CLINICAL-IMMUNOLOGICAL PROFILING AND PREDICTORS OF THROMBOSIS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME: DATA FROM A DEDICATED CLINIC AT A TERTIARY CENTRE

ABS1020 DAMAGE ACCRUAL AS A RISK FACTOR FOR THE DEVELOPMENT OF LYMPHOMA IN PRIMARY SJOGREN'S SYNDROME

ABS1092 OLDER PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME PRESENTING WITH ARTERIAL THROMBOSIS ARE AT RISK TO DEVELOP SMALL VESSEL INVOLVEMENT

OP0267 SINGLE-CELL TRANSCRIPTOMICS OF B CELLS TOWARDS THE UNDERSTANDING OF THE MECHANISMS LEADING TO THE PRODUCTION OF ANTIPHOSPHOLIPID ANTIBODIES IN THROMBOTIC PRIMARY ANTIPHOSPHOLIPID SYNDROME

OP0272 ANTIPHOSPHOLIPID ANTIBODIES NEGATIVIZATION IS ASSOCIATED WITH DECREASED RISK OF RECURRENT THROMBOSIS IN THROMBOTIC PRIMARY ANTIPHOSPHOLIPID SYNDROME

POS0471 Damage Assessment in Primary Sjogren's Syndrome

Damage Index for Antiphospholipid Syndrome (DIAPS): An AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) “Damage” Working Group Report on Strengths and Limitations

Bleeding events in thrombotic antiphospholipid syndrome: prevalence, severity, and associated damage accrual

OP0229 ADJUSTED GLOBAL ANTIPHOSPHOLIPID SYNDROME SCORE (aGAPSS) AT DIAGNOSIS AND PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES ARE STRONGER PREDICTORS OF RECURRENT THROMBOSIS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME

Predictors of damage accrual and its impact on health-related quality of life of thrombotic antiphospholipid syndrome: Independent validation of the damage index for antiphospholipid syndrome (DIAPS)

Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations

POS1318 DYSREGULATION OF CIRCULATING T FOLLICULAR CELLS, BUT NOT B CELLS, IS ASSOCIATED WITH ANTIPHOSPHOLIPID ANTIBODIES POSITIVITY IN PATIENTS WITH THROMBOTIC PRIMARY ANTIPHOSPHOLIPID SYNDROME

Predictors of Long-COVID-19 and its Impact on Quality of Life: Longitudinal Analysis at 3, 6 and 9 Months after Discharge from a Portuguese Centre

Collaborators (4)

David A Isenberg

Luis Graca

Danieli Andrade

Hannah Cohen

Make your next move.